IGCS20_1358

LOW BRCA 1/2 GERMLINE MUTATION RATE IN A FRENCH CANADIAN POPULATION

J Bernard*, W Mehros, M Renaud, J Grégoire, P Douville, A Sébastianelly, M Plante. Hôpital Dieu De Québec, Canada

Objective Universal genetic testing has become increasingly important in the management of women with epithelial tubo-ovarian and peritoneal carcinoma. Worldwide, the reported rates of deleterious BRCA mutation rate vary between 12–15%. We wanted to evaluate the rate in our population considering its specific genetic background (French Canadian ascertainment).

Method Mainstreaming genetic testing was implemented in our service in Mai 2017 and offered to all patients with epithelial tubo-ovarian or peritoneal carcinomas, except mucinous and borderline tumors. The data was prospectively collected in a database and retrospectively analyzed.

Results A total of 214 patients were tested in our center, 169 (79%) were high grade serious carcinomas (HGSC). Overall, 137 patients had no mutation (64%). Deleterious BRCA 1/2 mutations were observed in 10 patients (4.7%), 4 BRCA1 and 6 BRCA2, nearly all were in HGSC (9). Other non BRCA-mutations (ATM, RAD51C, RAD51D, BRIPI, CDH1, MRE11, MSH6, MUTYH, PALB2 and PMS2) were observed in an additional 18 patients (8.4%): 16 HGSC, 1 endometriot and 1 carcinosarcoma. VUS were seen in 57 patients (26.7%) of which 4 were BRCA1/2 VUS. No deleterious mutations were identified in clear cell carcinomas and seen in only one low grade serous carcinoma.

Conclusion In our specific French Canadian population, the deleterious germline BRCA mutation rate was surprisingly low (4.7%), less than half the rate reported in the literature. Based on Health Canada’s current approval, only a small proportion of our patients could access PARPi therapy. Hopefully canadian indications for PARPi will soon include non-BRCA and somatic mutations.

IGCS20_1359

IS A VAGINECTOMY ENOUGH OR IS A PELVIC EXENTERATION ALWAYS REQUIRED FOR SURGICAL TREATMENT OF RECURRENT CYSTIC CANCER?

1G Vizielli*, 1T Lucia, 1C Conte, 1V Chiantera, 1V Gallotta, 1N Foschi, 1M Arcieri, 4G Ferrandina, 4A Fagotti, 4F Zattori, 4G Scambia, 4A Ercoli. 1Dipartimento Scienze della Salute della Donna e del Bambino e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; 2Division of Gynecologic Oncology, University of Palermo, Palermo, Italy; 3Division of Urology, Fondazione Policlinico Universitario ‘Agostino Gemelli’ IRCCS, Rome, Italy; 4Division of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Padua, Italy; 5Department of Obstetrics and Gynecology, University of Messina, Messina, Italy

Introduction Ovarian cancer (OVCA) is a lethal gynecologic malignancy. Patients with high-grade and low-grade disease carry a poor prognosis from chemoresistance and decreased induction of apoptosis. We hypothesized persistent activation of the unfolded protein response (UPR) with upregulation of CHOP and XAF-1 arms, would overcome apoptotic arrest, leading to death in chemo-sensitive and resistant OVCA.

Methods Patient-derived and commercially available HG and LG OVCA cells were cultured and treated with celastrol, a potent UPR activator. Cell viability was assessed using Incucyte. Protein lysates of cells treated with celastrol were analyzed using Western blot and Caspase-Glo. RNA was analyzed using real-time PCR. Transient knock down (KD) of XAF-1 and CHOP was performed using siRNA.

Results Celastrol induced cell death in chemo-sensitive and resistant OVCA lines in the nanomolar range. Celastrol induced the UPR.

CHOP was preferentially upregulated upstream of mitochondrial depolarization and induction of the intrinsic apoptotic pathway. There was a reciprocal rise in XAF-1 RNA/protein levels and fall in XIAP with UPR activation. KD of XAF-1 decreased the cytotoxic effect of celastrol. KD of

IGCS20_1360

TREATMENT OF OVARIAN CANCER VIA INDUCTION OF CELLULAR STRESS AND THE UNFOLDED PROTEIN RESPONSE (UPR)

A Paradon*, A Alvero, M Rummans, I Winer. Detroit Medical Center/Wayne State University, USA

Introduction Ovarian cancer (OVCA) is a lethal gynecologic malignancy. Patients with high-grade and low-grade disease carry a poor prognosis from chemoresistance and decreased induction of apoptosis. We hypothesized persistent activation of the unfolded protein response (UPR) with upregulation of CHOP and XAF-1 arms, would overcome apoptotic arrest, leading to death in chemo-sensitive and resistant OVCA.

Methods Patient-derived and commercially available HG and LG OVCA cells were cultured and treated with celastrol, a potent UPR activator. Cell viability was assessed using Incucyte. Protein lysates of cells treated with celastrol were analyzed using Western blot and Caspase-Glo. RNA was analyzed using real-time PCR. Transient knock down (KD) of XAF-1 and CHOP was performed using siRNA.

Results Celastrol induced cell death in chemo-sensitive and resistant OVCA lines in the nanomolar range. Celastrol induced the UPR.

CHOP was preferentially upregulated upstream of mitochondrial depolarization and induction of the intrinsic apoptotic pathway. There was a reciprocal rise in XAF-1 RNA/protein levels and fall in XIAP with UPR activation. KD of XAF-1 decreased the cytotoxic effect of celastrol. KD of